Epizyme Net Profit Margin 2012-2022 | EPZM

Epizyme net profit margin from 2012 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Epizyme Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.04B $-0.24B -607.69%
2021-12-31 $0.04B $-0.25B -660.53%
2021-09-30 $0.03B $-0.27B -782.35%
2021-06-30 $0.03B $-0.26B -775.76%
2021-03-31 $0.02B $-0.25B -1136.36%
2020-12-31 $0.02B $-0.23B -1540.00%
2020-09-30 $0.01B $-0.22B -1981.82%
2020-06-30 $0.01B $-0.20B -1523.08%
2020-03-31 $0.02B $-0.19B -1105.88%
2019-12-31 $0.02B $-0.17B -704.17%
2019-09-30 $0.03B $-0.14B -463.33%
2019-03-31 $0.03B $-0.12B -403.33%
2017-06-30 $0.02B $-0.12B -705.88%
2016-12-31 $0.01B $-0.11B -1571.43%
2016-09-30 $0.01B $-0.10B -1212.50%
2016-06-30 $0.00B $-0.10B -9600.00%
2016-03-31 $0.00B $-0.09B -4700.00%
2015-12-31 $0.00B $-0.13B -4400.00%
2015-09-30 $0.01B $-0.13B -1041.67%
2015-06-30 $0.02B $-0.12B -610.00%
2015-03-31 $0.03B $-0.11B -389.29%
2014-12-31 $0.04B $-0.06B -137.50%
2014-09-30 $0.07B $-0.02B -36.36%
2014-06-30 $0.07B $-0.01B -21.21%
2014-03-31 $0.07B $-0.00B -4.17%
2013-12-31 $0.07B $-0.00B -5.88%
2013-06-30 $0.04B $-0.01B -25.64%
2013-03-31 $0.04B $-0.01B -20.51%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.075B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00